But maybe of more use are the hedges the company with $11 trillion in assets has articulated for a number of concerns that are currently weighing on investors' minds, according to strategists led by ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...
Novo Nordisk shares climbed over 3% in Wednesday's pre-market trading as U.S. stock futures rebounded from a tech-driven ...
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular dis ...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...